COMPANY

Palatin Technologies

HQ: Princeton, NJ source · palatin.com ↗ · Mid-Atlantic

Keywords: metabolic obesity Prader-Willi syndrome Bardet-Biedl syndrome ophthalmology Hypoactive Sexual Desire Disorder Heart Failure With Preserved Ejection Fraction Ulcerative Colitis Ulcerative Colitis Acute Ulcerative Ulcerative Colitis Flare Kidney Disease Dry Eye Dry Eye Syndromes Female Sexual Arousal Disorder Asthma Hypertension Sexual Arousal Disorder Bremelanotide PL8177 PL9643 PL-3994 PL3994

Location: Princeton, NJ · source · Oct 15, 2026

Profile checked Oct 10, 2026

$34.4MRaised (2 yrs)11Trials (company is sponsor)

Raises and deals from press releases

Deal Boehringer Ingelheim deal · amount not disclosed · announced Sep 22, 2025 Company release ↗
Source quote
- Sep 22, 2025 · Company release ↗
  “About the Collaboration On August 18, 2025 , Palatin entered into a strategic partnership with Boehringer Ingelheim to develop potential first-in-class melanocortin receptor–targeted treatments for patients with retinal diseases”

From the company’s own releases; this list is partial. All raises and deals

Timeline

Nov 12, 2025 Raise Follow-on offering: $18.2M (total, as published), announced Nov 12, 2025. Source: SEC filing. source ↗
May 7, 2025 Raise Follow-on offering: $11.5M (total, as published), announced May 7, 2025. Source: SEC filing. source ↗
Feb 7, 2025 Raise Follow-on offering — Registered direct: $4.7M (total, as published), announced Feb 7, 2025. Source: SEC filing. source ↗
Aug 5, 2024 Trial start 2: A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity source ↗
Dec 26, 2022 Trial start II: A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease source ↗
Sep 15, 2022 Trial start 2: Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) source ↗
Dec 30, 2021 Trial start 3: A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye source ↗
Nov 12, 2020 Trial start Phase 2: Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects source ↗
2015-01 Trial start Phase 3: 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder source ↗
2014-12 Trial start Phase 3: 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder source ↗
2011-06 Trial start Phase 2: Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder source ↗
2008-04 Trial start Phase 2: Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension source ↗
2006-02 Trial start Phase 2: Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD) source ↗

Funding

Raised: $34.4M. Last 2 years.

Nov 12, 2025 Follow-on offering: $18.2M (total, as published), announced Nov 12, 2025. Source: SEC filing. source ↗
May 7, 2025 Follow-on offering: $11.5M (total, as published), announced May 7, 2025. Source: SEC filing. source ↗
Feb 7, 2025 Follow-on offering — Registered direct: $4.7M (total, as published), announced Feb 7, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 11

Record	Title	Phase	Status	Start	Primary completion
NCT04318145	Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects	Phase 2	Terminated	Nov 12, 2020	Dec 8, 2023 (actual)
NCT06565611	A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity	2	Active, not recruiting	Aug 5, 2024	Feb 5, 2025 (actual)
NCT05466890	Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)	2	Active, not recruiting	Sep 15, 2022	Feb 10, 2025 (actual)
NCT05709444	A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease	II	Completed	Dec 26, 2022	Apr 26, 2024 (actual)
NCT05201170	A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye	3	Completed	Dec 30, 2021	Sep 1, 2023 (actual)
NCT02333071	1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder	Phase 3	Completed	2014-12	2016-07 (actual)
NCT02338960	2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder	Phase 3	Completed	2015-01	2016-08 (actual)
NCT01382719	Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder	Phase 2	Completed	2011-06	2012-09 (actual)
NCT01304628	Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma	Phase 2	Withdrawn	Not listed	Not listed
NCT00686803	Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension	Phase 2	Completed	2008-04	2008-07 (actual)
NCT00425256	Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)	Phase 2	Completed	2006-02	2007-05 (actual)